ASTRO ’18: ViewRay displays MRIdian capabilities, clinical outcomes

By News Release


ViewRay, Inc.has announced that the company's MRIdian® and MRIdian Linac – the world's only FDA-cleared MRI-guided radiation therapy systems – will be featured at the Annual Meeting of the American Society for Radiation Oncology (ASTRO). ASTRO 2018 will be held October 21-24, 2018 in San Antonio, TX and will include a number of presentations highlighting the unique capabilities, clinical experience and patient outcomes of ViewRay's MRIdian and MRIdian Linac.

At ASTRO, ViewRay will highlight the four key elements that differentiate MRIdian Linac from any other radiotherapy system on the market today. These unique capabilities include:

  • Visualization of the tumor and surrounding organs with high-definition, high-contrast MR  imaging (SEE)
  • Daily on-table treatment adaptation to accommodate anatomical positioning changes that regularly occur from one day of treatment to the next (SHAPE)
  • Real-time soft tissue image guidance and beam control during radiation delivery (STRIKE)
  • Ability to fit into existing standard linear accelerator vaults (SIZE)

Visitors to the company's booth # 1121 can see these one-of-a-kind features first-hand in an up-close simulated MRI-guided ROAR™ (Real-time On-table Adaptive Radiotherapy) patient treatment. ViewRay's booth will also feature presentations from seven MRIdian users covering a spectrum of topics from commissioning and re-contouring to novel applications and real-time on-table adaptive therapy.

Two Industry Expert Theater sessions at ASTRO will highlight imaging of tumor response and clinical outcomes using MRIdian MRI-guided Radiotherapy. Related sessions include:

  • "MRI-Guided Radiotherapy: Imaging of Tumor Response to Therapy", to be held Sunday, October 21 from 2:45–3:45 p.m. with presentations by Carri Glide-Hurst, Ph.D. (Henry Ford), Nicola Dinapoli, M.D., Ph.D. (Gemelli), and John Chetley Ford, Ph.D. (University of Miami
  • "MRI-Guided Radiotherapy Clinical Outcomes: A Summary of Prospective Trials" to be held Tuesday, October 23 from 12:30–1:30 p.m. with presentations by Michael Bassetti, M.D., Ph.D. (University of Wisconsin), Imran Zoberi, M.D. (Washington University), and Amar Kishan, M.D. (UCLA)

As part of the ASTRO scientific sessions, an interactive panel entitled "Current and Future Applications for MR-guided Radiotherapy with Real-time Adaptive Radiotherapy" will be held on Tuesday, October 23 from 1:00 p.m. - 2:30 p.m. to further explore MR-guided radiotherapy implementation, early clinical outcomes, and areas of future research. Early clinical experience suggests that use of MRI-guided radiotherapy, particularly utilizing on-table adaptive radiotherapy with daily assessment of plan quality and optimization, may translate to a clinical benefit in locally advanced pancreatic cancer, liver tumors and oligometastatic disease. The panel will feature presentations from Percy Lee, M.D. and Michael Steinberg, M.D. from UCLA, Olga Green, Ph.D. from Washington University School of Medicine in St. Louis, and Benjamin Movsas, M.D. from Henry Ford Health System.

For a full schedule of MRIdian-focused presentations and events at ASTRO or to book a product demonstration, please visit

Back To Top

ASTRO ’18: ViewRay displays MRIdian capabilities, clinical outcomes.  Appl Rad Oncol. 

By News Release| October 17, 2018
Categories:  Section|Technologies

About the Author

News Release

News Release


Copyright © Anderson Publishing, Ltd

    Agility CMS